Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) EUR/USD
1,0769 +0,0002 (+0,02%) Bitcoin EUR
59.615,19 +985,65 (+1,68%) CMC Crypto 200
1.339,75 +62,77 (+4,92%)
Aligos Therapeutics, Inc. (ALGS)
Dopo ore:
- GlobeNewswire
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
- NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies - This is the second NIH-funding received to advance the development of ALG-097558 - First in human Phase 1 study evaluating single/multiple doses of ALG-097558 in healthy volunteers is ongoing - Aligos plans to continue to seek external funding to advance ALG-097558 beyond the ongoing Phase 1 first in human study SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE
- GlobeNewswire
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administra
- GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2023. “We continue to make important progress in advancing our portfolio of drug candidates,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics.
